WILEX AG

WILEX is a biopharmaceutical company developing novel cancer therapies for the treatment of various tumors including renal and breast cancer. Therapies are based upon biologic targets directly connected to cancer progression and pathogenesis in order to provide effective and well-tolerated treatment and enhance patients' quality of life.The company has a portfolio of cancer drug candidates ranging from research to late stage clinical development. The company has two therapeutic platforms: antibodies, which specifically target the tumor cells, and small molecules, which block metastasis and primary tumor growth.
Currently, WILEX has three drug candidates in clinical development. The lead compound Rencarex® (WX-G250), a targeted antibody therapy for the treatment of solid tumors, is currently in a pivotal clinical Phase III trial as an adjuvant treatment of non-metastatic renal cell cancer (RCC). The company’s non-cytotoxic uPA and serine protease inhibitors WX-UK1 and WX-671, which are in clinical development, are assigned for the anti-metastatic treatment of breast cancer and other solid tumors. The company’s pre-clinical research pipeline currently consists of two projects.
WILEX was founded in 1997 by clinical oncologists from the Technical University of Munich.

Contact Details: Grillparzerstr. 16 Munich 81675 Germany Tel: 49 (0)89 41 31 38 0 Fax: 49 (0)89 41 31 38 99 Email: investors@wilex.com WWW: www.wilex.com/

Recent Publications by WILEX AG:
Epitope mapping using phage display peptide libraries. Phage libraries displaying millions of peptides with randomized sequences...	15th July, 2009	Wilex AG, Grillparzerstr. 10, 81675 Munich, Germany.	Methods Mol Biol. 2009;524:181-201. DOI Direct Link

BioNews Results for WILEX AG:
WILEX AG: WILEX starts Phase I trial for WX-554 and thereby achieves second milestone of the strategic allianc	Pharma Live:  Nov 18 2009 1:13AM Matching: wilex ag
Wilex and Fox Chase Cancer Center Embark on Second Phase of Breast Cancer Clinical Trial Using Oral Agents to	Fox Chase Cancer Center:  Nov 16 2009 5:41PM Matching: wilex ag
Wilex releases 9-month Financial Report 2009: Significant progress in development projects	Pharma Live:  Oct 13 2009 1:13PM Matching: wilex ag
WILEX AG: WILEX receives approval for Phase I trial with MEK inhibitor WX-554	Pharma Live:  Oct 2 2009 3:52PM Matching: wilex ag

WILEX AG Patents:
US Patent No.	Title
7608623	Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
6872702	Inhibitors for urokinase receptor
6906032	Cyclic peptidomimetic urokinase receptor antagonists
7038074	Arginine mimetics as factor X.sub.a inhibitors
7045504	Cyclic peptidomimetic urokinase receptor antagonists
→View more WILEX AG patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 641 times since April 2007, the link to the organisation's website has been followed 78 times

Recent Search Terms used to find this page: wilex | Wilex AG patents | wilex | wilex | wilex | .

Search for more companies in Munich

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for WILEX AG